english.prescrire.org > Spotlight > "Spotlight"
"Spotlight"

In the September issue of Prescrire International:
Raltegravir in HIV-infected children at least 2 years of age

FREE DOWNLOAD This sample page from the "New Products" section takes a look at raltegravir, now authorised in the EU for HIV-infected children aged at least 2 years. This integrase inhibitor may be a useful addition to optimised antiretroviral treatment for children in treatment failure.
Full text available for free download.

Summary

  • The first integrase inhibitor to be approved for children
     
  • Antiretroviral effect similar to that observed in adults in treatment failure
     
  • No first-line evaluation available

Full text available for free download.

 ©Prescrire 1 September 2014

"Raltegravir in HIV-infected children at least 2 years of age" Prescrire Int 2014; 23 (152): 206. (Pdf, free)